E815
TEAS SECTION 8 & 15 RECEIVED
07/17/2026
Back to search
Official data from USPTO
XILIO THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
XILIO THERAPEUTICS
ST13
US500000088981516Class
42
Filing
88981516
Registration
6421510
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
07/17/2026
Trademark type
Word
Nice classes
42
Filing date
02/03/2020
Registration date
07/13/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/13/2021
Last transaction
07/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
03/02/2021
First use in commerce
03/02/2021
Drawing code
4
Owner type
03
Owner location
Waltham, MA, US
Examiner
BERLIN, JUSTIN E
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
XILIO DEVELOPMENT, INC.
Akrevia Therapeutics, Inc.
Representatives
Valerie Brennan Plave Koch PLC
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Pharmaceutical research and development; research and development of pharmaceuticals for the treatment of cancerall of the foregoing excluding research and development services for pharmaceutical products for sleep disorderscentral nervous disorders (other than cancers of the central nervous system)neurological disorders (other than cancers of the neurological system)
Publications
History of USPTO decisions and trademark events.
34 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/13/2026
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/27/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/27/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/27/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/13/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
06/10/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/09/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/04/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/03/2021
DPCC
DIVISIONAL PROCESSING COMPLETE
05/03/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/26/2021
IUAF
USE AMENDMENT FILED
04/06/2021
EX1G
SOU EXTENSION 1 GRANTED
04/06/2021
EXT1
SOU EXTENSION 1 FILED
04/06/2021
DRRR
DIVISIONAL REQUEST RECEIVED
04/06/2021
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
04/06/2021
EEXT
SOU TEAS EXTENSION RECEIVED
04/06/2021
EISU
TEAS STATEMENT OF USE RECEIVED
04/06/2021
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/08/2020
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
11/25/2020
CHPB
POST PUBLICATION AMENDMENT - ENTERED
10/28/2020
APET
ASSIGNED TO PETITION STAFF
10/27/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/14/2020
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
10/11/2020
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
09/16/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
06/29/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/02/2020
PUBO
PUBLISHED FOR OPPOSITION
06/02/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/24/2020
DOCK
ASSIGNED TO EXAMINER
04/22/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/07/2020
NWAP
NEW APPLICATION ENTERED
02/06/2020
Continuous trademark protection
Get notified about every new filing that threatens XILIO THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.